Welcome to our dedicated page for Vifor Pharma news (Ticker: GNHAY), a resource for investors and traders seeking the latest updates and insights on Vifor Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vifor Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vifor Pharma's position in the market.
The collaboration between Travere Therapeutics (TVTX) and Vifor Pharma aims to commercialize sparsentan, a potential first-in-class treatment for rare kidney disorders FSGS and IgAN. Under the agreement, Vifor obtains exclusive rights in Europe, Australia, and New Zealand, while Travere receives a USD 55 million upfront payment and could earn up to USD 135 million in milestone payments. Sparsentan is currently undergoing pivotal phase-III trials and has Orphan Drug Designation in both the U.S. and Europe for these conditions.
Vifor Pharma announces key updates in the 2021 European Society of Cardiology (ESC) guidelines regarding heart failure treatment. The guidelines now recommend periodic screening for iron deficiency in heart failure patients and highlight the use of Ferinject® to reduce hospitalization rates. Additionally, Veltassa® is proposed to assist RAASi initiation in patients with hyperkalemia. These updates emphasize the potential to improve patient outcomes and treatment standards.
FAQ
What is the market cap of Vifor Pharma (GNHAY)?
